Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma.

Dobrosotskaya IY, Hammer GD, Schteingart DE, Maturen KE, Worden FP.

Endocr Pract. 2011 May-Jun;17(3):e59-62. doi: 10.4158/EP10390.CR.

PMID:
21454232
2.

Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature.

El Ghorayeb N, Rondeau G, Latour M, Cohade C, Olney H, Lacroix A, Perrotte P, Sabourin A, Mazzuco TL, Bourdeau I.

Medicine (Baltimore). 2016 Mar;95(13):e3180. doi: 10.1097/MD.0000000000003180.

3.

Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.

Reidy-Lagunes DL, Lung B, Untch BR, Raj N, Hrabovsky A, Kelly C, Gerst S, Katz S, Kampel L, Chou J, Gopalan A, Saltz LB.

Oncologist. 2017 Sep;22(9):1102-1106. doi: 10.1634/theoncologist.2016-0459. Epub 2017 May 30.

PMID:
28559412
4.

[¹⁸F]Fluorodeoxyglucose positron emission tomography-guided therapy in metastatic adrenocortical carcinoma: an illustrative case.

Chuang HH, Deniz F, Sircar K, Jimenez C, Rubin De Celis C, Wood CG, Habra MA.

J Clin Oncol. 2012 Sep 10;30(26):e246-9. doi: 10.1200/JCO.2011.40.6710. Epub 2012 May 29. No abstract available.

5.

Adjunctive treatment of adrenocortical carcinoma.

Terzolo M, Berruti A.

Curr Opin Endocrinol Diabetes Obes. 2008 Jun;15(3):221-6. doi: 10.1097/MED.0b013e3282fdf4c0. Review.

PMID:
18438168
6.

Lipiodol avid liver metastases from adrenocortical carcinoma; prospects for therapy?

Nye E, Butler P, Clingan PC, Morris DL.

Anticancer Res. 2001 Mar-Apr;21(2B):1445-7.

PMID:
11396229
7.

Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma.

Pacella CM, Stasi R, Bizzarri G, Pacella S, Graziano FM, Guglielmi R, Papini E.

Eur J Radiol. 2008 Apr;66(1):88-94. Epub 2007 May 10.

PMID:
17498906
8.

Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma.

Liu-Chittenden Y, Jain M, Kumar P, Patel D, Aufforth R, Neychev V, Sadowski S, Gara SK, Joshi BH, Cottle-Delisle C, Merkel R, Yang L, Miettinen M, Puri RK, Kebebew E.

Cancer Med. 2015 Jul;4(7):1060-8. doi: 10.1002/cam4.449. Epub 2015 Mar 13.

9.

Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine.

Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C, Strasburger C, Allolio B, Fassnacht M.

J Clin Endocrinol Metab. 2008 Jun;93(6):2057-62. doi: 10.1210/jc.2007-2564. Epub 2008 Mar 11. Erratum in: J Clin Endocrinol Metab. 2008 Aug;93(8):3230. Ritte, Christian [corrected to Ritter, Christian].

PMID:
18334586
10.

Adrenocortical carcinoma: the management of metastatic disease.

Fay AP, Elfiky A, Teló GH, McKay RR, Kaymakcalan M, Nguyen PL, Vaidya A, Ruan DT, Bellmunt J, Choueiri TK.

Crit Rev Oncol Hematol. 2014 Nov;92(2):123-32. doi: 10.1016/j.critrevonc.2014.05.009. Epub 2014 Jun 4. Review.

11.

[A Case of Adrenocortical Carcinoma Successfully Treated with Multimodal Therapy].

Bando S, Ishii G, Yamada H, Kimura T, Furuta N, Egawa S.

Hinyokika Kiyo. 2016 Jan;62(1):15-9. Japanese.

12.

A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.

Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, Schrump D, Bartlett D, Choyke P, Robey R, Hung E, Steinberg SM, Bates S, Fojo T.

Cancer. 2002 May 1;94(9):2333-43.

13.

Surgical management of adrenocortical carcinoma.

Ranvier GG, Inabnet WB 3rd.

Endocrinol Metab Clin North Am. 2015 Jun;44(2):435-52. doi: 10.1016/j.ecl.2015.02.008. Epub 2015 Mar 17. Review.

PMID:
26038210
14.

Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice.

Martarelli D, Pompei P, Baldi C, Mazzoni G.

Cancer Chemother Pharmacol. 2008 Apr;61(5):809-17. Epub 2007 Jun 21.

PMID:
17581752
16.

Adrenocortical oncocytic carcinoma with recurrent metastases: a case report and review of the literature.

Argyriou P, Zisis C, Alevizopoulos N, Kefaloyannis EM, Gennatas C, Petraki CD.

World J Surg Oncol. 2008 Dec 17;6:134. doi: 10.1186/1477-7819-6-134.

17.

Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.

Seki M, Nomura K, Hirohara D, Kanazawa M, Sawada T, Takasaki K, Demura H.

Endocr Relat Cancer. 1999 Dec;6(4):529-33.

18.

Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.

Kerkhofs TM, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller HH, Skogseid B, Leboulleux S, Mantero F, Haak HR, Fassnacht M.

J Clin Endocrinol Metab. 2013 Dec;98(12):4759-67. doi: 10.1210/jc.2013-2281. Epub 2013 Sep 20.

19.

[Mitotane in the treatment of adrenal carcinoma].

Sane T.

Duodecim. 2010;126(17):2040-6. Review. Finnish.

PMID:
21053521
20.

[Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].

Lecka A, Ginalska-Malinowska M.

Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2006;12(3):234-6. Polish.

PMID:
17020662

Supplemental Content

Support Center